3,507 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd acquired 3,507 shares of DexCom, Inc., valued at approximately $239,000, in the first quarter of the year.
• Several institutional investors, including Vanguard Group and Jennison Associates, have increased their stakes in DexCom, leading to 97.75% of the stock being owned by institutional investors and hedge funds.
• DexCom reported earnings of $0.48 per share for the latest quarter, beating analysts' expectations and showing a 15.2% revenue increase year-over-year, with forecasts suggesting a continued positive trend.

S Bank Fund Management Ltd purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,507 shares of the medical device company's stock, valued at approximately $239,000.

Several other institutional investors have also made changes to their positions in DXCM. Vanguard Group Inc. raised its position in shares of DexCom by 2.0% in the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock valued at $3,240,763,000 after purchasing an additional 925,882 shares during the period. Jennison Associates LLC boosted its stake in DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after buying an additional 2,879,489 shares in the last quarter. Nuveen LLC acquired a new stake in shares of DexCom in the 1st quarter valued at $554,893,000. Northern Trust Corp boosted its stake in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of DexCom by 171.0% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after purchasing an additional 2,015,971 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Down 0.3%

NASDAQ DXCM opened at $79.96 on Thursday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a 50 day simple moving average of $83.28 and a two-hundred day simple moving average of $80.19. The stock has a market cap of $31.36 billion, a P/E ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter last year, the business posted $0.43 EPS. The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Citigroup reiterated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Truist Financial began coverage on DexCom in a research note on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Finally, UBS Group increased their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $99.89.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the sale, the executive vice president directly owned 95,102 shares in the company, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,656 shares of company stock worth $2,412,191. 0.32% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.